Douglas Adkins1, Jessica Ley2, Loren Michel3, Tanya M Wildes3, Wade Thorstad4, Hiram A Gay4, Mackenzie Daly4, Jason Rich5, Randal Paniello5, Ravindra Uppaluri5, Ryan Jackson5, Kathryn Trinkaus6, Brian Nussenbaum5. 1. Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States; Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States. Electronic address: dadkins@dom.wustl.edu. 2. Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States. 3. Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States; Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States. 4. Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States. 5. Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States; Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO, United States. 6. Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States; Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, United States.
Abstract
OBJECTIVES: We previously reported the efficacy of nab-paclitaxel added to cisplatin, 5-FU, and cetuximab (APF-C) followed by concurrent high dose bolus cisplatin and radiation therapy (CRT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). In this phase II trial, we determined the efficacy of APF (without cetuximab) followed by CRT in similar patients. MATERIALS AND METHODS: Eligible patients had stage III-IV oropharynx (OP), larynx, or hypopharynx SCC and adequate organ function and performance status. T1 tumors were excluded. Patients were treated with three cycles of APF followed by CRT. Efficacy endpoints included two-year disease-specific survival (DSS), progression-free survival (PFS), overall survival (OS), and relapse rate. RESULTS: Thirty patients were enrolled. Most patients were smokers (77%) with bulky T3/4 (73%) and N2/3 (83%) tumors. Analyses were stratified for human papilloma virus (HPV) status: HPV-related OPSCC (n=17; 57%) and HPV-unrelated HNSCC (n=13; 43%). With a minimum follow-up of 21months, relapse occurred in 1 (3%) patient. Two-year DSS was 94% in HPV-related OPSCC and 100% in HPV-unrelated HNSCC. Two-year PFS was 94% in HPV-related OPSCC and 100% in HPV-unrelated HNSCC. Two-year OS was 94% in HPV-related OPSCC and 92% in HPV-unrelated HNSCC. Causes of death were relapse (1), treatment-related mortality (1), and co-morbidity (1). Two patients with HPV-unrelated HNSCC treated with APF declined CRT and remained free of relapse at 36 and 28months of follow-up. CONCLUSION: This phase II trial demonstrated favorable two-year DSS, PFS, and OS and a low relapse rate in HPV-unrelated HNSCC and HPV-related OPSCC treated with APF followed by CRT.
OBJECTIVES: We previously reported the efficacy of nab-paclitaxel added to cisplatin, 5-FU, and cetuximab (APF-C) followed by concurrent high dose bolus cisplatin and radiation therapy (CRT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). In this phase II trial, we determined the efficacy of APF (without cetuximab) followed by CRT in similar patients. MATERIALS AND METHODS: Eligible patients had stage III-IV oropharynx (OP), larynx, or hypopharynx SCC and adequate organ function and performance status. T1 tumors were excluded. Patients were treated with three cycles of APF followed by CRT. Efficacy endpoints included two-year disease-specific survival (DSS), progression-free survival (PFS), overall survival (OS), and relapse rate. RESULTS: Thirty patients were enrolled. Most patients were smokers (77%) with bulky T3/4 (73%) and N2/3 (83%) tumors. Analyses were stratified for human papilloma virus (HPV) status: HPV-related OPSCC (n=17; 57%) and HPV-unrelated HNSCC (n=13; 43%). With a minimum follow-up of 21months, relapse occurred in 1 (3%) patient. Two-year DSS was 94% in HPV-related OPSCC and 100% in HPV-unrelated HNSCC. Two-year PFS was 94% in HPV-related OPSCC and 100% in HPV-unrelated HNSCC. Two-year OS was 94% in HPV-related OPSCC and 92% in HPV-unrelated HNSCC. Causes of death were relapse (1), treatment-related mortality (1), and co-morbidity (1). Two patients with HPV-unrelated HNSCC treated with APF declined CRT and remained free of relapse at 36 and 28months of follow-up. CONCLUSION: This phase II trial demonstrated favorable two-year DSS, PFS, and OS and a low relapse rate in HPV-unrelated HNSCC and HPV-related OPSCC treated with APF followed by CRT.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Athanassios Argiris; Dwight E Heron; Ryan P Smith; Seungwon Kim; Michael K Gibson; Stephen Y Lai; Barton F Branstetter; Donna M Posluszny; Lin Wang; Raja R Seethala; Sanja Dacic; William Gooding; Jennifer R Grandis; Jonas T Johnson; Robert L Ferris Journal: J Clin Oncol Date: 2010-11-15 Impact factor: 44.544
Authors: Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison Journal: J Clin Oncol Date: 2014-06-23 Impact factor: 44.544
Authors: Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316
Authors: Ezra E W Cohen; Theodore G Karrison; Masha Kocherginsky; Jeffrey Mueller; Robyn Egan; Chao H Huang; Bruce E Brockstein; Mark B Agulnik; Bharat B Mittal; Furhan Yunus; Sandeep Samant; Luis E Raez; Ranee Mehra; Priya Kumar; Frank Ondrey; Patrice Marchand; Bettina Braegas; Tanguy Y Seiwert; Victoria M Villaflor; Daniel J Haraf; Everett E Vokes Journal: J Clin Oncol Date: 2014-07-21 Impact factor: 44.544
Authors: Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis Journal: Cancer Discov Date: 2013-04-25 Impact factor: 39.397
Authors: Juliette B Scantlebury; Jingqin Luo; Wade L Thorstad; Samir K El-Mofty; James S Lewis Journal: Hum Pathol Date: 2013-04-06 Impact factor: 3.466
Authors: Merrill S Kies; Floyd Christopher Holsinger; J Jack Lee; William N William; Bonnie S Glisson; Heather Y Lin; Jan S Lewin; Lawrence E Ginsberg; Katharine A Gillaspy; Erminia Massarelli; Lauren Byers; Scott M Lippman; Waun K Hong; Adel K El-Naggar; Adam S Garden; Vassiliki Papadimitrakopoulou Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: J F Ensley; J R Jacobs; A Weaver; J Kinzie; J Crissman; J A Kish; G Cummings; M Al-Sarraf Journal: Cancer Date: 1984-09-01 Impact factor: 6.860
Authors: Kai C C Johnson; Jessica Ley; Peter Oppelt; Jingxia Lu; Hiram A Gay; Mackenzie Daly; Ryan Jackson; Jason Rich; Patrik Pipkorn; Randal C Paniello; Jose Zevallos; Wade Thorstad; Douglas R Adkins Journal: Med Oncol Date: 2019-10-08 Impact factor: 3.064
Authors: Fatima Ardito; Mario R Pellegrino; Donatella Perrone; Giuseppe Troiano; Armando Cocco; Lorenzo Lo Muzio Journal: Onco Targets Ther Date: 2017-11-13 Impact factor: 4.147
Authors: Qiang Xu; Meiyu Fang; Jing Zhu; Haoru Dong; Jun Cao; Lin Yan; Fransisca Leonard; Felix Oppel; Holger Sudhoff; Andreas M Kaufmann; Andreas E Albers; Xu Qian Journal: Int J Biol Sci Date: 2020-07-19 Impact factor: 6.580